Current status and perspectives of biopharmaceutical drugs

Biotechnology and Bioprocess Engineering

Volumn 17, Issue 5, 2012, Pages 900-911

  Ryu, Jae Kuk ^a   Kim, Hyo Sun ^b   Nam, Doo Hyun ^b  

^a Hanmi Pharmaceutical Co Ltd   (South Korea)

^b Yeungnam University   (South Korea)

Author keywords

Biobetter; Biopharmaceutical drug; Biosimilar; Display technology; Glycoengineering; Pegylation; Protein engineering

Indexed keywords

BIOBETTER; BIOPHARMACEUTICAL DRUGS; BIOSIMILAR; DISPLAY TECHNOLOGIES; GLYCOENGINEERING; PEGYLATION; PROTEIN ENGINEERING;

ANTIBODIES; BIOACTIVITY; BIOCHEMICAL ENGINEERING; COMMERCE; DISPLAY DEVICES; GENETIC ENGINEERING; TECHNOLOGY;

DRUG PRODUCTS;

ADALIMUMAB; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ASPARAGINASE MACROGOL; BETA1A INTERFERON; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; DACLIZUMAB; DRUG ANTIBODY; ECALLANTIDE; ETANERCEPT; GENERIC DRUG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN INSULIN; INFLIXIMAB; INTERFERON BETA SERINE; MONOCLONAL ANTIBODY; NATALIZUMAB; PEGADEMASE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT CYTOKINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GROWTH FACTOR; RECOMBINANT HORMONE; SOMATREM; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANTIBODY PRODUCTION; ANTIBODY TITER; BACTERIAL INFECTION; BIOENGINEERING; CROHN DISEASE; DRUG BINDING SITE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG PURIFICATION; DRUG SAFETY; GLYCOENGINEERING; GLYCOSYLATION; HAIRY CELL LEUKEMIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOGENICITY; INFUSION RELATED REACTION; MYELOID LEUKEMIA; PEGYLATION; PHAGE DISPLAY; PLASMA HALF LIFE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN ENGINEERING; PSORIASIS; PURE RED CELL ANEMIA; REVIEW; RHEUMATOID ARTHRITIS; SEVERE COMBINED IMMUNODEFICIENCY; SIDE EFFECT; TUBERCULOSIS;

EID: 84871196747     PISSN: 12268372     EISSN: 19763816     Source Type: Journal    
DOI: 10.1007/s12257-012-0095-1     Document Type: Review

References (91)

1. IMS Health Inc. (2009) "IMS Health Midas".
2. Nam, D. H. and D. D. Y. Ryu (1999) Biomolecular engineering and drug development. Biotechnol. Bioproc. Eng. 4: 83-92.
3. Ryu, D. D. Y. and D. H. Nam (2000) Recent progress in biomolecular engineering. Biotechnol. Progr. 16: 2-16.
4. Moors, E. S. and H. Shellekens (2010) The strengths and weaknesses of the European biosimilar regulatory pathway. Nat. Biotechnol. 28: 28-32.
5. Rathore, A. S. (2009) Follow-on protein products: Scientific issues, developments and challenges. Trends Biotechnol. 27: 698-705.
6. Woodcock, J., J. Griffin, R. Behrman, B. Cherney, T. Crescenzi, B. Frase, D. Hixon, C. Joneckis, S. Kozlowski, A. Rosenberg, L. Schrager, E. Shacter, R. Temple, K. Webber, and H. Winkle (2007) The FDA's assessment of follow-on protein products: A historical perspective. Nat. Rev. Drug Discov. 6: 437-442.
7. Joung J., J. S. Robertson, E. Griffiths, I. Knezevic, and WHO Informal Consultation Group (2008). WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007. Biologic. 36: 269-276.
8. Knezevic, I. and E. Griffiths (2011) Biosimilars -global issues, national solutions. Biologic. 39: 252-255.
9. Kang, H.-N. (2011) Summary of the diverse situation of similar biotherapeutic products in the selected countries (August 2010). Biologic. 39: 304-307.
10. Knezevic, I. (2011) Evaluation of similar biotherapeutic products (SBPs): Scientific principles and their implementation. Biologic. 39: 256-261.
11. Wenzel, R. G. (2008) Biosimilars: Illustration of scientific issues in two examples. Am. J. Health Syst. Pharm. 65: 9-15.
12. Salgado, E. and J. J. Gómez-Reino (2011) The risk of tuberculosis in patients treated with TNF antagonists. Expert Rev. Clin. Immunol. 7: 329-340.
13. Tavazzi, E., P. Ferrante, and K. Khalili (2011) Progressive multifocal leukoencephalopathy: An unexpected complication of modern therapeutic monoclonal antibody therapies. Clin. Microbiol. Infect. 17: 1776-1780.
14. Rosenberg, A. S. (2003) Immunogenicity of biological therapeutics: A hierarchy of concerns. Develop. Biol. (Basel) 112: 15-21.
15. Barbosa, M. D. F. S. (2011) Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov. Today 16: 345-353.
16. Tamilvanan, S., N. L. Raja, B. Sa, and S. K. Basu (2010) Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body. J. Drug Target. 18: 489-498.
17. Massa, G., M. Vanderschueren-Lodeweyckx, and R. Bouillon (1993) Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. Clin. Endocrinol. 38: 137-142.
18. Schellenkens, H. and N. Casadevall (2004) Immunogenicity of recombinant human proteins: Causes and consequences. J. Neurol. 251: 4-9.
19. Frost, H. (2005) Antibody-mediated side effects of recombinant proteins. Toxicol. 209: 155-160.
20. Berman, E., G. Heller, S. Kempin, T. Gee, L. L. Tran, and B. Clarkson (1990) Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 75: 839-845.
21. Wussow, P. V., D. Jakschies, M. Freund, R. Hehlmann, F. Brockhaus, H. Hochkeppel, M. Horisberger, and H. Deicher (1991) Treatment of anti-recombinant interferon-A2 antibody positive CML patients with natural interferon-A. Brit. J. Haematol. 78: 210-216.
22. van der Eijk, A. A., J. M. Vrolijk, and B. L. Haagmans (2006) Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C. New Engl. J. Med. 354: 1323-1324.
23. Casadevall, N., J. Nataf, B. Viron, A. Kolta, J. J. Kiladjian, P. Martin-Dupont, P. Michaud, T. Papo, V. Ugo, I. Teyssandier, B. Varet, and P. Mayeux (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. New Engl. J. Med. 346: 469-475.
24. Locatelli, F., L. Del Vecchio, and P. Pozzoni (2007) Pure red-cell aplasia "epidemic"-mystery completely revealed? Periton. Dial. Int. 27: 303-307.
25. McKoy, J. M., R. E. Stonecash, D. Cournoyer, J. Rossert, A. R. Nissenson, D. W. Raisch, N. Casadevall, and C. L. Bennett (2008) Epoetin-Associated pure red cell aplasia: Past, present, and future considerations. Transfusion 48: 1754-1762.
26. Shin, S. K., S. P. Pack, J. G. Oh, N. K. Kang, M. H. Chang, Y. H. Chung, S. J. Kim, J. W. Lee, and T. H. Heo (2011) Anti-erythropoietin and anti-thrombopoietin antibodies induced after administration of recombinant human erythropoietin. Int. Immunopharmacol. 11: 2237-2241.
27. Lusher, J. M. (2000) Inhibitor antibodies to factor VIII and factor IX: Management. Seminar Thromb. Hemost. 26: 179-188.
28. Ehrenforth, S., W. Kreuz, I. Scharrer, R. Linde, M. Funk, T. Güngör, B. Krackhardt, and B. Kornhuber (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339: 594-598.
29. Warrier, I., B. M. Ewenstein, M. A. Koerper, A. Shapiro, N. Key, D. DiMichele, R. T. Miller, J. Pasi, G. E. Rivard, S. S. Sommer, J. Katz, F. Bergmann, R. Ljung, P. Petrini, and J. M. Lusher (1997) Factor IX inhibitors and anaphylaxis in hemophilia B. J. Pediatr. Hematol. Oncol. 19: 23-27.
30. Fineberg, S. E., J. A. Galloway, N. S. Fineberg, M. J. Rathbun, and S. Hufferd (1983) Immunogenicity of recombinant DNA human insulin. Diabetol. 25: 465-469.
31. Oberg, K. and G. Alm (1997) The incidence and clinical significance of antibodies to interferon-A in patients with solid tumors. Biotherapy 10: 1-5
32. Steis, R. G., J. W. Smith 2nd, W. J. Urba, J. W. Clark, L. M. Itri, L. M. Evans, C. Schoenberger, and D. L. Longo (1988) Resistance to recombinant interferon a-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. New Engl. J. Med. 318: 1409-1413.
33. Bonetti, P., G. Diodati, C. Drago, C. Casarin, S. Scaccabarozzi, G. Realdi, A. Ruol, and A. Alberti (1994) Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon a-2a. J. Hepatol. 20: 416-420.
34. Douglas, D. D., J. Rakela, H. J. Lin, F. B. Hollinger, H. F. Taswell, A. J. Czaja, J. B. Gross, M. L. Anderson, K. Parent, and C. R. Fleming (1993) Randomized controlled trial of recombinant a-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. Digest. Dis. Sci. 38: 601-607.
35. Larocca, A. P., S. C. Leung, S. G. Marcus, C. B. Colby, and E. C. Borden (1989) Evaluation of neutralizing antibodies in patients treated with recombinant interferon-ß ser. J. Interferon Res. 9: 51-60.
36. Abdul-Ahad, A. K., A. R. Galazka, M. Revel, M. Biffoni, and E. C. Borden (1997) Incidence of antibodies to interferon-ß in patients treated with recombinant human interferon-ß1a from mammalian cells. Cytokines Cell. Mol. Ther. 3: 27-32.
37. Myhr, K. M., C. Ross, H. I. Nyland, K. Bendtzen, and C. A. Vedeler (2000) Neutralizing antibodies to interferon (IFN) a-2a and IFN ß-1a or IFN ß-1b in MS are not cross-reactive. Neurol. 55: 1569-1572.
38. Antonelli, G., F. Bagnato, C. Pozzilli, E. Simeoni, S. Bastianelli, M. Currenti, F. de Pisa, C. Fieschi, C. Gasperini, M. Salvetti, and F. Dianzani (1998) Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-ß1a. J. Interferon Cytokine Res. 18: 345-350.
39. Ullenhag, G., C. Bird, P. Ragnhammar, J. E. Frödin, K. Strigård, A. OIsterborg, R. Thorpe, H. Mellstedt, and M. Wadhwa (2001) Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation. Clin. Immunol. 99: 65-74.
40. Wadhwa, M., C. Bird, J. Fagerberg, R. Gaines-Das, P. Ragnhammar, H. Mellstedt, and R. Thorpe (1996) Production of neutralizing granulocyte- macrophage colony-stimulating factor (GMCSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin. Exp. Immunol. 104: 351-358.
41. Ragnhammar, P., H. J. Friesen, J. E. Frödin, A. K. Lefvert, M. Hassan, A. Osterborg, and H. Mellstedt (1994) Induction of antirecombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 84: 4078-4087.
42. Boven, K., S. Stryker, J. Knight, A. Thomas, M. van Regenmortel, D. M. Kemeny, D. Power, J. Rossert, and N. Casadevall (2005) The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 67: 2346-2353.
43. Lusher, J. M., S. Arkin, C. F. Abildgaard, and R. S. Schwartz (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate previously untreated patient study group. New Engl. J. Med. 328: 453-459.
44. Bray, G. L., E. D. Gomperts, S. Courter, R. Gruppo, E. M. Gordon, M. Manco-Johnson, A. Shapiro, E. Scheibel, G. White, and M. Lee (1994) A multicenter study of recombinant factor VIII (recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 83: 2428-2435.
45. Kreuz, W., C. E. Ettingshausen, A. Zyschka, J. Oldenburg, I. M. Saguer, S. Ehrenforth, and T. Klingebiel (2002) Inhibitor development in previously untreated patients with hemophilia A: A prospective long-term follow-up comparing plasma-derived and recombinant products. Seminar Thromb. Hemost. 28: 285-290.
46. Charles, S. A. (2005) SuperGenerics: A better alternative for biogenerics. Drug Discov. Today 10: 533-535.
47. Sinclair, A. M. and S. Elliott (2005) Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. J. Pharm. Sci. 94: 1626-1635.
48. Rensen, P. C., L. A. Sliedregt, M. Ferns, E. Kieviet, S. M. van Rossenberg, S. H. van Leeuwen, T. J. van Berkel, and E. A. Biessen (2001) Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J. Biol. Chem. 276: 37577-37584.
49. Kim, H. J. and H.-J. Kim (2009) The effect of cell concentration on alpha 2,3-sialyltransferase activity in attachment culture of a human erythropoietin-producing Chinese hamster ovary cell line. Biotechnol. Bioproc. Eng. 14: 406-413
50. Ohls, R. K. and A. Dai (2004) Long-Acting erythropoietin: Clinical studies and potential uses in neonates. Clin. Perinatol. 31: 77-89.
51. Egrie, J. C., E. Dwyer, J. K. Browne, A. Hitz, and M. A. Lykos (2003) Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol. 31: 290-299.
52. Tanswell, P., N. Modi D. Combs, and T. Danays (2002) Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin. Pharmacokinet. 41: 1229-1245.
53. McVie-Wylie, A. J., K. L. Lee, H. Qiu, X. Jin, H. Do, R. Gotschall, B. L. Thurberg, C. Rogers, N. Raben, M. O'Callaghan, W. Canfield, L. Andrews, J. M. McPherson, and R. J. Mattaliano (2008) Biochemical and pharmacological characterization of different recombinant acid a-glucosidase preparations evaluated for the treatment of Pompe disease. Mol. Genet. Metab. 94: 448-455.
54. Zhu, Y., J. L. Jiang, N. K. Gumlaw, J. Zhang, S. D. Bercury, R. J. Ziegler, K. Lee, M. Kudo, W. M. Canfield, T. Edmunds, C. Jiang, R. J. Mattaliano, and S. H. Cheng (2009) Glycoengineered acid a-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol. Ther. 17: 954-963.
55. Morgan, C. and D. Fernandes (2011) Designing biobetter monoclonal antibody therapeutics by glycoengineering. Intern. Pharm. Ind. 1: 38-44.
56. Bailon, P. and C. Y. Won (2009) PEG-modified biopharmaceuticals. Expert Opin. Drug. Deliv. 6: 1-16.
57. Pasut, G. and F. M. Veronese (2009) PEGylation for improving the effectiveness of therapeutic biomolecules. Drugs Today 45: 687-695.
58. Jevsevar, S., M. Kunstelj, and V. G. Porekar (2010) PEGylation of therapeutic proteins. Biotechnol. J. 5: 113-128.
59. Davis, S., A. Abuchowski, Y. K. Park, and F. F. Davis (1981) Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin. Exp. Immunol. 46: 649-652.
60. Asselin, B. L., J. C. Whitin, D. J. Coppola, I. P. Rupp, S. E. Sallan, and H. J. Cohen (1993) Comparative pharmacokinetic studies of three asparaginase preparations. J. Clin. Oncol. 11: 1780-1786.
61. Bailon, P., A. Palleroni, C. A. Schaffer, C. L. Spence, W. J. Fung, J. E. Porter, G. K. Ehrlich, W. Pan, Z. X. Xu, M. W. Modi, A. Farid, W. Berthold, and M. Graves (2001) Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem. 12: 195-202.
62. Glue, P., J. W. S. Fang, R. Rouzier-Panis, C. Raffanel, R. Sabo, S. K. Gupta, M. Salfi, S. Jacobs, and The Hepatitis C Intervention Therapy Group (2000) Pegylated interferon-A2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Ther. 68: 556-567.
63. Grigg, A., P. Solal-Celigny, P. Hoskin, K. Taylor, A. McMillan, R. Forstpointner, P. Bacon, J. Renwick, W. Hiddemann, and International Study Group (2003) Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk. Lymphoma 44: 1503-1508.
64. Macdougall, I. C., R. Robson, S. Opatrna, X. Liogier, A. Pannier, P. Jordan, F. C. Dougherty, and B. Reigner (2006) Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 1: 1211-1215.
65. Olson, K., R. Gehant, and V. Mukku (1997) Preparation and characterization of poly(ethylene glycol)ylated human growth hormone antagonist. pp. 170-180. In: J. M. Harris and S. Zalipsky (eds.). Poly(ethylene glycol) chemistry and biological applications. American Chemical Society, Washington D. C., USA.
66. Choy, E. H., B. Hazleman, M. Smith, K. Moss, L. Lisi, D. G. Scott, J. Patel, M. Sopwith, and D. A. Isenberg (2002) Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A phase II double-blinded, randomized, dose-escalating trial. Rheumatol. 41: 1133-1137.
67. Sundy, J. S., N. J. Ganson, S. J. Kelly, E. L. Scarlett, C. D. Rehrig, W. Huang, and M. S. Hershfield (2007) Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 56: 1021-1028.
68. Hong, H. J. and S. T. Kim (2002) Antibody engineering. Biotechnol. Bioproc. Eng. 7: 150-154.
69. Yoon, S., Y.-S. Kim, H. Shim, and J. Chung (2010) Current perspectives on therapeutic antibodies. Biotechnol. Bioproc. Eng. 15: 709-715.
70. Sandhu, J. S. (1992) Protein engineering of antibodies. Crit. Rev. Biotechnol. 12: 437-462.
71. Kipriyanov, S. M. and M. Little (1999) Generation of recombinant antibodies. Mol. Biotechnol. 12: 173-201.
72. Weiner, L. M. (2006) Fully human therapeutic monoclonal antibodies. J. Immunother. 29: 1-9.
73. Carter, P. J. (2011) Introduction to current and future protein therapeutics: A protein engineering perspective. Exp. Cell Res. 317: 1261-1269.
74. Jazayeri, J. A. and G. J. Carroll (2008) Fc-based cytokines: Prospects for engineering superior therapeutics. BioDrugs 22: 11-26.
75. Pugsley, M. K. (2001) Etanercept Immunex. Curr. Opin. Investig. Drugs 2: 1725-1731.
76. Krueger, G. G. and K. P. Callis (2003) Development and use of alefacept to treat psoriasis. J. Am. Acad. Dermatol. 49: 87-97.
77. Lundquist, L. (2007) Abatacept: A novel therapy approved for the treatment of patients with rheumatoid arthritis. Adv. Ther. 24: 333-345.
78. McDermott, M. F. (2009) Rilonacept in the treatment of chronic inflammatory disorders. Drugs Today 45: 423-430.
79. Wojciechowski, D. and F. Vincenti (2010) How the development of new biological agents may help minimize immunosuppression in kidney transplantation: The impact of belatacept. Curr. Opin. Organ Transplant. 15: 697-702.
80. Molineux, G. (2011) The development of romiplostim for patients with immune thrombocytopenia. Ann. N. Y. Acad. Sci. doi: 10.1111/j.1749-6632.2011. 05975.
81. Skerra, A. (2007) Alternative non-Antibody scaffolds for molecular recognition. Curr. Opin. Biotechnol. 18: 295-304.
82. Gebauer, M. and A. Skerra (2009) Engineered protein scaffolds as next-generation antibody therapeutics. Curr. Opin. Chem. Biol. 13: 245-255.
83. Löfblom, J., J. Feldwisch, V. Tolmachev, J. Carlsson, S. Ståhl, and F. Y. Frejd (2010) Affibody molecules: Engineered proteinsfor therapeutic, diagnostic and biotechnological applications. FEBS Lett. 584: 2670-2680.
84. Stumpp, M. T., H. K. Binz, and P. Amstutz (2008) DARPins: A new generation of protein therapeutics. Drug Discov. Today 13: 695-701.
85. Skerra, A. (2008) Alternative binding proteins: Anticalins -harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J. 275: 2677-2683.
86. Bradbury, A. R., S. Sidhu, S. Dübel, and J. McCafferty (2011) Beyond natural antibodies: The power of in vitro display technologies. Nat. Biotechnol. 29: 245-254.
87. Löfblom, J. (2011) Bacterial display in combinatorial protein engineering. Biotechnol. J. 6: 1115-1129.
88. Machold, K. P. and J. S. Smolen (2003) Adalimumab -A new TNF-A antibody for treatment of inflammatory joint disease. Expert Opin. Biol. Ther. 3: 351-360.
89. Lehmann, A. (2006) Ecallantide (Dyax/Genzyme). Curr. Opin. Investig. Drugs 7: 282-290.
90. Ki, M. K., K. J. Kang, and H. Shim (2010) Phage display selection of EGFR-specific antibodies by capture-sandwich panning. Biotechnol. Bioproc. Eng. 15: 152-156.
91. Bostrom, J., S. F. Yu, D. Kan, B. A. Appleton, C. V. Lee, K. Billeci, W. Man, F. Peale, S. Ross, C. Wiesmann, and G. Fuh (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323: 1610-1614.